

LEGISLATIVE ACTION

Senate Comm: RCS 02/11/2020 House

Senate Amendment (with title amendment) Delete lines 32 - 126 and insert: purposes of this subsection, <u>the term</u> "other pharmaceutical services" means the monitoring of the patient's drug therapy and assisting the patient in the management of his or her drug therapy, and includes <u>reviewing</u>, <u>and making recommendations</u> regarding, review of the patient's drug therapy and health care

The Committee on Health Policy (Diaz) recommended the following:

10 <u>status in</u> communication with the patient's prescribing health

11 care provider as licensed under chapter 458, chapter 459,

1 2 3

4

5 6

7

8

9



12 chapter 461, or chapter 466, or a similar statutory provision in 13 another jurisdiction, or such provider's agent or such other 14 persons as specifically authorized by the patient, regarding the 15 drug therapy. However, nothing in this subsection may not be 16 interpreted to permit an alteration of a prescriber's 17 directions, the diagnosis or treatment of any disease, the initiation of any drug therapy, the practice of medicine, or the 18 19 practice of osteopathic medicine, unless otherwise permitted by 20 law. The term "practice of the profession of pharmacy" also 21 includes any other act, service, operation, research, or 22 transaction incidental to, or forming a part of, any of the 23 foregoing acts, requiring, involving, or employing the science 24 or art of any branch of the pharmaceutical profession, study, or 25 training, and shall expressly permit a pharmacist to transmit information from persons authorized to prescribe medicinal drugs 26 27 to their patients. The practice of the profession of pharmacy 28 also includes the administration of vaccines to adults pursuant 29 to s. 465.189 and the preparation of prepackaged drug products 30 in facilities holding Class III institutional pharmacy permits. The term also includes ordering and evaluating any laboratory or 31 32 clinical testing; conducting patient assessments; and modifying, 33 discontinuing, or administering medicinal drugs pursuant to s. 34 465.0125 by a consultant pharmacist.

35 Section 2. Section 465.0125, Florida Statutes, is amended 36 to read:

465.0125 Consultant pharmacist license; application, renewal, fees; responsibilities; rules.-

39 (1) The department shall issue or renew a consultant40 pharmacist license upon receipt of an initial or renewal

37

38

588-03234A-20

431574

41	application that which conforms to the requirements for
42	consultant pharmacist initial licensure or renewal as adopted
43	promulgated by the board by rule and a fee set by the board not
44	to exceed \$250. <u>To be licensed as a consultant pharmacist, a</u>
45	pharmacist must complete additional training as required by the
46	board.
47	(a) A consultant pharmacist may provide medication
48	management services in a health care facility within the
49	framework of a written collaborative practice agreement between
50	the pharmacist and a health care facility medical director or a
51	physician licensed under chapter 458 or chapter 459, a podiatric
52	physician licensed under chapter 461, or a dentist licensed
53	under chapter 466 who is authorized to prescribe medicinal
54	drugs. A consultant pharmacist may provide medication management
55	services, conduct patient assessments, and order and evaluate
56	laboratory or clinical testing only for patients of the health
57	care practitioner with whom the consultant pharmacist has a
58	written collaborative practice agreement.
59	(b) A written collaborative practice agreement must outline
60	the circumstances under which the consultant pharmacist may:
61	1. Order and evaluate any laboratory or clinical tests to
62	promote and evaluate patient health and wellness, and monitor
63	drug therapy and treatment outcomes.
64	2. Conduct patient assessments as appropriate to evaluate
65	and monitor drug therapy.
66	3. Modify or discontinue medicinal drugs as outlined in the
67	agreed-upon patient-specific order or preapproved treatment
68	protocol under the direction of a physician. However, a
69	consultant pharmacist may not modify or discontinue medicinal

588-03234A-20



70	drugs prescribed by a health care practitioner who does not have
71	a written collaborative practice agreement with the consultant
72	pharmacist.
73	4. Administer medicinal drugs.
74	<u>(c) A</u> The consultant pharmacist shall <u>maintain</u> be
75	responsible for maintaining all drug, patient care, and quality
76	assurance records as required by law and, with the collaborating
77	practitioner, shall maintain written collaborative practice
78	agreements that must be available upon request from or upon
79	inspection by the department.
80	(d) This subsection does not authorize a consultant
81	pharmacist to diagnose any disease or condition.
82	(e) For purposes of this subsection, the term "health care
83	facility" means an ambulatory surgical center or hospital
84	licensed under chapter 395, an alcohol or chemical dependency
85	treatment center licensed under chapter 397, an inpatient
86	hospice licensed under part IV of chapter 400, a nursing home
87	licensed under part II of chapter 400, an ambulatory care center
88	as defined in s. 408.07, or a nursing home component under
89	chapter 400 within a continuing care facility licensed under
90	chapter 651 for establishing drug handling procedures for the
91	safe handling and storage of drugs. The consultant pharmacist
92	may also be responsible for ordering and evaluating any
93	laboratory or clinical testing when, in the judgment of the
94	consultant pharmacist, such activity is necessary for the proper
95	performance of the consultant pharmacist's responsibilities.
96	Such laboratory or clinical testing may be ordered only with
97	regard to patients residing in a nursing home facility, and then
98	only when authorized by the medical director of the nursing home

431574

99	facility. The consultant pharmacist must have completed such
100	additional training and demonstrate such additional
101	qualifications in the practice of institutional pharmacy as
102	shall be required by the board in addition to licensure as a
103	registered pharmacist.
104	(2) Notwithstanding the provisions of subsection (1), a
105	
106	======================================
107	And the title is amended as follows:
108	Delete line 5
109	and insert:
110	465.0125, F.S.; requiring a pharmacist to complete
111	additional training to be licensed as a consultant
112	pharmacist; authorizing a consultant pharmacist to